BCR and inflammatory bowel disease: Strikingly, across 1–4 doses of vaccine, patients with IBD treated with anti-TNF showed significantly lower avidity IgG binding to S compared with people in the healthy control group and patients with IBD treated with IL-12/23 (Figure 7A), consistent with the BCR-Seq data presented above.